Advertisement
Advertisement
U.S. Markets open in 4 hrs 51 mins
Advertisement
Advertisement
Advertisement
Advertisement

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.4100-0.0200 (-0.45%)
At close: 03:59PM EST
4.4100 0.00 (0.00%)
After hours: 04:20PM EST
Advertisement

Reviva Pharmaceuticals Holdings, Inc.

19925 Stevens Creek Boulevard
Suite 100
Cupertino, CA 95014
United States
408 501 8881
https://revivapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. Laxminarayan Bhat Ph.D.Founder, CEO, Pres & Director600.05kN/A1965
Mr. Narayan PrabhuChief Financial Officer275kN/A1972
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Corporate Governance

Reviva Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement